Progress on hematoma expansion mechanism and hemostatic therapy of spontaneous intracerebral hemorrhage

doi:10.3969/j.issn.1672-6731.2021.02.006

Abstract

Abstract:

Spontaneous intracerebral hemorrhage (SICH) is a severe subtype of stroke. Hematoma expansion could occur in the short term after symptom onset in most patients, leading to neurological deterioration and mortality. Therefore, early hemostasis treatment is essential to save patients' lives and improve prognosis. Currently, the hemostatic agents used for intracerebral hemorrhage are mainly antifibrinolytic drugs and recombinant activated factor Ⅶ. However, there is no decisive evidence for the clinical benefit of hemostatic drugs in patients with intracerebral hemorrhage. To provide reference for clinical choice of drugs, this article reviews the hematoma expansion mechanism and hemostatic therapy of spontaneous intracerebral hemorrhage.

Key words: Cerebral hemorrhage, Hematoma, Hemostatics, Review

摘要：

自发性脑出血是一种严重的脑卒中亚型，大多数患者发病短期即可出现血肿扩大，导致神经系统症状恶化和病死，因此早期止血治疗对挽救患者生命、改善预后至关重要。目前用于脑出血的止血药以抗纤溶类药物和重组凝血因子Ⅶa为主，但至今尚未获得脑出血患者可从止血药治疗中获益的临床证据。本文对自发性脑出血血肿扩大机制和常用止血药研究进展进行概述，以为临床选择用药提供参考。

关键词: 脑出血, 血肿, 止血药, 综述

LI Yu-jian, ZHENG Jun. Progress on hematoma expansion mechanism and hemostatic therapy of spontaneous intracerebral hemorrhage[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(2): 94-100.

李育健, 郑峻. 自发性脑出血血肿扩大机制及止血治疗进展[J]. 中国现代神经疾病杂志, 2021, 21(2): 94-100.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.02.006

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I2/94

References

[1] Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, Abajobir AA, Abate KH, Abd-Allah F, Abejie AN, Abyu GY, Ademi Z, Agarwal G, Ahmed MB, Akinyemi RO, Al-Raddadi R, Aminde LN, Amlie-Lefond C, Ansari H, Asayesh H, Asgedom SW, Atey TM, Ayele HT, Banach M, Banerjee A, Barac A, Barker-Collo SL, Bärnighausen T, Barregard L, Basu S, Bedi N, Behzadifar M, Béjot Y, Bennett DA, Bensenor IM, Berhe DF, Boneya DJ, Brainin M, Campos-Nonato IR, Caso V, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Christensen H, Criqui MH, Damasceno A, Dandona L, Dandona R, Davletov K, de Courten B, deVeber G, Dokova K, Edessa D, Endres M, Faraon EJA, Farvid MS, Fischer F, Foreman K, Forouzanfar MH, Gall SL, Gebrehiwot TT, Geleijnse JM, Gillum RF, Giroud M, Goulart AC, Gupta R, Gupta R, Hachinski V, Hamadeh RR, Hankey GJ, Hareri HA, Havmoeller R, Hay SI, Hegazy MI, Hibstu DT, James SL, Jeemon P, John D, Jonas JB, Jó?wiak J, Kalani R, Kandel A, Kasaeian A, Kengne AP, Khader YS, Khan AR, Khang YH, Khubchandani J, Kim D, Kim YJ, Kivimaki M, Kokubo Y, Kolte D, Kopec JA, Kosen S, Kravchenko M, Krishnamurthi R, Kumar GA, Lafranconi A, Lavados PM, Legesse Y, Li Y, Liang X, Lo WD, Lorkowski S, Lotufo PA, Loy CT, Mackay MT, Abd El Razek HM, Mahdavi M, Majeed A, Malekzadeh R, Malta DC, Mamun AA, Mantovani LG, Martins SCO, Mate KK, Mazidi M, Mehata S, Meier T, Melaku YA, Mendoza W, Mensah GA, Meretoja A, Mezgebe HB, Miazgowski T, Miller TR, Ibrahim NM, Mohammed S, Mokdad AH, Moosazadeh M, Moran AE, Musa KI, Negoi RI, Nguyen M, Nguyen QL, Nguyen TH, Tran TT, Nguyen TT, Anggraini Ningrum DN, Norrving B, Noubiap JJ, O'Donnell MJ, Olagunju AT, Onuma OK, Owolabi MO, Parsaeian M, Patton GC, Piradov M, Pletcher MA, Pourmalek F, Prakash V, Qorbani M, Rahman M, Rahman MA, Rai RK, Ranta A, Rawaf D, Rawaf S, Renzaho AM, Robinson SR, Sahathevan R, Sahebkar A, Salomon JA, Santalucia P, Santos IS, Sartorius B, Schutte AE, Sepanlou SG, Shafieesabet A, Shaikh MA, Shamsizadeh M, Sheth KN, Sisay M, Shin MJ, Shiue I, Silva DAS, Sobngwi E, Soljak M, Sorensen RJD, Sposato LA, Stranges S, Suliankatchi RA, Tabarés-Seisdedos R, Tanne D, Nguyen CT, Thakur JS, Thrift AG, Tirschwell DL, Topor-Madry R, Tran BX, Nguyen LT, Truelsen T, Tsilimparis N, Tyrovolas S, Ukwaja KN, Uthman OA, Varakin Y, Vasankari T, Venketasubramanian N, Vlassov VV, Wang W, Werdecker A, Wolfe CDA, Xu G, Yano Y, Yonemoto N, Yu C, Zaidi Z, El Sayed Zaki M, Zhou M, Ziaeian B, Zipkin B, Vos T, Naghavi M, Murray CJL, Roth GA; GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016[J]. N Engl J Med, 2018, 379:2429-2437.
[2] Pinho J, Costa AS, Araújo JM, Amorim JM, Ferreira C. Intracerebral hemorrhage outcome:a comprehensive update[J]. J Neurol Sci, 2019, 398:54-66.
[3] Hostettler IC, Seiffge DJ, Werring DJ. Intracerebral hemorrhage: an update on diagnosis and treatment[J]. Expert Rev Neurother, 2019, 19:679-694.
[4] Wang P, Sun Y, Yi D, Xie Y, Luo Y. Clinical features of Chinese patients in different age groups with spontaneous intracerebral hemorrhage based on multicenter inpatient information[J]. Neurol Res, 2020, 42:657-664.
[5] Yan F, Yi Z, Hua Y, Shen Y, Li M, Ding Y, Chandra A, Ji X, Yue W. Predictors of mortality and recurrent stroke within five years of intracerebral hemorrhage[J]. Neurol Res, 2018, 40:466-472.
[6] Sembolini A, Romoli M, Pannacci U, Gambaracci G, Floridi P, Acciarresi M, Agnelli G, Alberti A, Venti M, Paciaroni M, Caso V. Acute hematoma expansion after spontaneous intracerebral hemorrhage:risk factors and impact on long-term prognosis[J]. Neurol Sci, 2020, 41:2503-2509.
[7] Fonseca S, Costa F, Seabra M, Dias R, Soares A, Dias C, Azevedo E, Castro P. Systemic inflammation status at admission affects the outcome of intracerebral hemorrhage by increasing perihematomal edema but not the hematoma growth[J]. Acta Neurol Belg, 2020.[ Epub ahead of print]
[8] Baldon IV, Amorim AC, Santana LM, Solla DJ, Kolias A, Hutchinson P, Paiva WS, Rosa-Júnior M. The extravasation of contrast as a predictor of cerebral hemorrhagic contusion expansion, poor neurological outcome and mortality after traumatic brain injury:a systematic review and meta-analysis[J]. PLoS One, 2020, 15:e0235561.
[9] Wartenberg KE, Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage:future directions[J]. Front Neurol Neurosci, 2015, 37:107-129.
[10] Thakkar MD, Qavi A, Singh AK, Maurya PK, Kulshreshtha D, Thacker AK, Deswal S. Clinical value of perilesional perfusion deficit measured by Technetium-99m-ECD single-photon emission computed tomography in hypertensive intracerebral hemorrhage[J]. World J Nucl Med, 2020, 19:246-254.
[11] Morotti A, Arba F, Boulouis G, Charidimou A. Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome:a meta-analysis[J]. Neurology, 2020, 95:632-643.
[12] Zhang F, Li H, Qian J, Zhang S, Tao C, You C, Yang M. Island sign predicts long-term poor outcome and mortality in patients with intracerebral hemorrhage[J]. World Neurosurg, 2018, 120:e304-312.
[13] Morotti A, Busto G, Bernardoni A, Tamborino C, Fainardi E. Association between perihematomal cerebral blood volume and intracerebral hemorrhage expansion:a computed tomography perfusion study[J]. Ann Neurol, 2019, 85:943-947.
[14] Zhao XY, Zhang XL. Establishment of composite experimental animal model of brain edema after cerebral hemorrhagic[J]. Ann Palliat Med, 2021.[ Epub ahead of print]
[15] Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, Che F, Chen X, Ren H, Hong M, Wang J. Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage[J]. Prog Neurobiol, 2019, 178:101610.
[16] Zhang J, Shan H, Tao L, Zhang M. Biological effects of hydrogen sulfide and its protective role in intracerebral hemorrhage[J]. J Mol Neurosci, 2020, 70:2020-2030.
[17] Hu R, Zhang C, Xia J, Ge H, Zhong J, Fang X, Zou Y, Lan C, Li L, Feng H. Long-term outcomes and risk factors related to hydrocephalus after intracerebral hemorrhage[J]. Transl Stroke Res, 2021, 12:31-38.
[18] Martí-Fàbregas J, Delgado-Mederos R, Martínez-Domeño A, Camps-Renom P, Guisado-Alonso D, Guasch-Jiménez M, Marrero-González P, Jiménez-Xarrié E, Marín R, Prats-Sánchez L. Clinical and radiological characteristics and outcome of wake-up intracerebral hemorrhage[J]. Sci Rep, 2020, 10:18749.
[19] Rass V, Lindner A, Ianosi BA, Schiefecker AJ, Loveys S, Kofler M, Rass S, Pfausler B, Beer R, Schmutzhard E, Helbok R. Early alterations in heart rate are associated with poor outcome in patients with intracerebral hemorrhage[J]. J Crit Care, 2021, 61:199-206.
[20] Menon G, Johnson SE, Hegde A, Rathod S, Nayak R, Nair R. Neutrophil to lymphocyte ratio-a novel prognostic marker following spontaneous intracerebral haemorrhage[J]. Clin Neurol Neurosurg, 2021, 200:106339.
[21] Chen R, Wang X, Anderson CS, Robinson T, Lavados PM, Lindley RI, Chalmers J, Delcourt C. Infratentorial intracerebral hemorrhage[J]. Stroke, 2019, 50:1257-1259.
[22] Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbec L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage[J]. Stroke, 1997, 28:1-5.
[23] Masotti L, Grifoni E, Migli L, Dei A, Spina R, Calamai I, Guazzini G, Micheletti I, Cosentino E, Pinto G, Vanni S. Prognostic determinants in patients with non traumatic intracerebral hemorrhage:a real life report[J]. Acta Clin Belg, 2020, 12:1-8.
[24] Okazaki S, Yamamoto H, Foster LD, Fukuda-Doi M, Koga M, Ihara M, Toyoda K, Palesch YY, Qureshi AI. Late neurological deterioration after acute intracerebral hemorrhage:a post hoc analysis of the ATACH-2 trial[J]. Cerebrovasc Dis, 2020, 49:26-31.
[25] Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T; Recombinant Activated Factor Ⅶ Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage[J]. Neurology, 2006, 66:1175-1181.
[26] Rodriguez-Luna D, Rubiera M, Ribo M, Coscojuela P, Piñeiro S, Pagola J, Hernandez-Guillamon M, Ibarra B, Romero F, Alvarez-Sabin J, Montaner J, Molina CA. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage[J]. Neurology, 2011, 77:1599-1604.
[27] Divani AA, Liu X, Petersen A, Lattanzi S, Anderson CS, Ziai W, Torbey MT, Moullaali TJ, James ML, Jafarli A, Mayer SA, Suarez JI, Hemphill JC, Di Napoli M. The magnitude of blood pressure reduction predicts poor in-hospital outcome in acute intracerebral hemorrhage[J]. Neurocrit Care, 2020, 33:389-398.
[28] Francoeur CL, Mayer SA; VISTA-ICH Collaborators. Acute blood pressure and outcome after intracerebral hemorrhage:the VISTA-ICH Cohort[J]. J Stroke Cerebrovasc Dis, 2021, 30:105456.
[29] Kuhn D, Tiffany L, Beher R, Boswell S, Giraldo D, Hassan M, Haase DJ, Khan A, Hassan S, Matta A, Sapru M, Tran QK. Blood pressure management in emergency department patients with spontaneous intracerebral hemorrhage[J]. Blood Press Monit, 2020, 25:318-323.
[30] Seiffge DJ, Goeldlin MB, Tatlisumak T, Lyrer P, Fischer U, Engelter ST, Werring DJ. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use[J]. J Neurol, 2019, 266:3126-3135.
[31] Jafari M, Di Napoli M, Lattanzi S, Mayer SA, Bachour S, Bershad EM, Damani R, Datta YH, Divani AA. Serum magnesium level and hematoma expansion in patients with intracerebral hemorrhage[J]. J Neurol Sci, 2019, 398:39-44.
[32] Faraoni D, Rahe C, Cybulski KA. Use of antifibrinolytics in pediatric cardiac surgery:where are we now[J]? Paediatr Anaesth, 2019, 29:435-440.
[33] Alanwar A, Abbas AM, Hussain SH, Elhawwary G, Mansour DY, Faisal MM, Elshabrawy A, Eltaieb E. Oral micronised flavonoids versus tranexamic acid for treatment of heavy menstrual bleeding secondary to copper IUD use:a randomised double-blind clinical trial[J]. Eur J Contracept Reprod Health Care, 2018, 23:365-370.
[34] Lee PL, Yang KS, Tsai HW, Hou SK, Kang YN, Chang CC. Tranexamic acid for gastrointestinal bleeding:a systematic review with meta-analysis of randomized clinical trials[J]. Am J Emerg Med, 2020.[Epub ahead of print]
[35] van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions[J]. Cochrane Database Syst Rev, 2019, 4:CD011385.
[36] Nielsen VG, Ford PM. The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis[J]. J Thromb Thrombolysis, 2018, 46:365-370.
[37] Foreman PM, Chua M, Harrigan MR, Fisher WS 3rd, Tubbs RS, Shoja MM, Griessenauer CJ. Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis:a case-control study[J]. Clin Neurol Neurosurg, 2015, 139:66-69.
[38] Malekpour M, Kulwin C, Bohnstedt BN, Radmand G, Sethia R, Mendenhall SK, Weyhenmeyer J, Hendricks BK, Leipzig T, Payner TD, Shah MV, Scott J, DeNardo A, Sahlein D, Cohen-Gadol AA. Effect of short-term ε-aminocaproic acid treatment on patients undergoing endovascular coil embolization following aneurysmal subarachnoid hemorrhage[J]. J Neurosurg, 2017, 126:1606-1613.
[39] Simon RP, Oromendia C, Sanso LM, Ramos LG, Rajwani K. Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding:a case series[J]. Pulm Pharmacol Ther, 2020, 60:101871.
[40] Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid:a pilot study[J]. Neurocrit Care, 2004, 1:47-51.
[41] Lum ZC, Manoukian MAC, Pacheco CS, Nedopil AJ, Giordani M, Meehan JP. Intravenous tranexamic acid versus topical aminocaproic acid:which method has the least blood loss and transfusion rates[J]? J Am Acad Orthop Surg Glob Res Rev, 2018, 2:e072.
[42] Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, Roos YB. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage[J]. Cochrane Database Syst Rev, 2013:CD001245.
[43] Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW, Kruyt ND, Willems PWA, Wolfs JFC, de Beer FC, Kieft H, Nanda D, van der Pol B, Roks G, de Beer F, Halkes PHA, Reichman LJA, Brouwers PJAM, van den Berg-Vos RM, Kwa VIH, van der Ree TC, Bronner I, van de Vlekkert J, Bienfait HP, Boogaarts HD, Klijn CJM, van den Berg R, Coert BA, Horn J, Majoie CBLM, Rinkel GJE, Roos YBWEM, Vandertop WP, Verbaan D; ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA):a randomised controlled trial[J]. Lancet, 2021, 397:112-118.
[44] HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT):an international randomised, double-blind, placebo-controlled trial[J]. Lancet, 2020, 395:1927-1936.
[45] Mahmood A, Needham K, Shakur-Still H, Harris T, Jamaluddin SF, Davies D, Belli A, Mohamed FL, Leech C, Lotfi HM, Moss P, Lecky F, Hopkins P, Wong D, Boyle A, Wilson M, Darwent M, Roberts I. Effect of tranexamic acid on intracranial haemorrhage and infarction in patients with traumatic brain injury:a pre-planned substudy in a sample of CRASH-3 trial patients[J]. Emerg Med J, 2020.[Epub ahead of print]
[46] Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage[J]. Neurosurgery, 2005, 57:837-844.
[47] Chornenki NLJ, Um KJ, Mendoza PA, Samienezhad A, Swarup V, Chai-Adisaksopha C, Siegal DM. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid:a systematic review and meta-analysis[J]. Thromb Res, 2019, 179:81-86.
[48] Arumugam A, Rahman NA, Theophilus SC, Shariffudin A, Abdullah JM. Tranexamic acid as antifibrinolytic agent in non traumatic intracerebral hemorrhages[J]. Malays J Med Sci, 2015, 22(Spec Issue):62-71.
[49] Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2):an international randomised, placebo-controlled, phase 3 superiority trial[J]. Lancet, 2018, 391:2107-2115.
[50] Kim CH, Lee SW, Kim YH, Sung SK, Son DW, Song GS. Predictors of hematoma enlargement in patients with spontaneous intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict conservative management[J]. Korean J Neurotrauma, 2019, 15:126-134.
[51] Jiang C, Wang J, Wang J, Zhang J; THE-ICH investigators. THE-ICH, Rationale and design of a randomized, double-blind trial evaluating the efficacy of tranexamic acid on hematoma expansion and peri-hematomal edema in patients with spontaneous intracerebral hemorrhage within 4.5 h after symptom onset:the THE-ICH trial protocol[J]. J Stroke Cerebrovasc Dis, 2020, 29:105136.
[52] Willems A, De Groote F, Dumoulin M, Fils JF, Van der Linden P. Aprotinin versus tranexamic acid in children undergoing cardiac surgery:an observational study[J]. Eur J Cardiothorac Surg, 2019, 56:688-695.
[53] Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Angelini GD, Flather M, Taggart DP; ART (Arterial Revascularization Trial) Investigators. Safety of perioperative aprotinin administration during isolated coronary artery bypass graft surgery:insights from the ART (Arterial Revascularization Trial)[J]. J Am Heart Assoc, 2018, 7:e007570.
[54] Chang Z, Chu X, Liu Y, Liu D, Feng Z. Use of recombinant activated factor Ⅶ for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia:a systematic review and meta-analysis of randomized controlled trials[J]. J Crit Care, 2020, 62:164-171.
[55] Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor Ⅶ with human albumin (r Ⅶ a-FP) in patients with congenital F Ⅶ deficiency[J]. Hematology, 2020, 25:17-25.
[56] Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; Recombinant Activated Factor Ⅶ Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor Ⅶ for acute intracerebral hemorrhage[J]. N Engl J Med, 2005, 352:777-785.
[57] Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of recombinant activated factor Ⅶ for acute intracerebral hemorrhage[J]. N Engl J Med, 2008, 358:2127-2137.
[58] Mayer SA, Davis SM, Skolnick BE, Brun NC, Begtrup K, Broderick JP, Diringer MN, Steiner T; FAST trial investigators. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor Ⅶ[J]? Stroke, 2009, 40:833-840.
[59] Sutherland CS, Hill MD, Kaufmann AM, Silvaggio JA, Demchuk AM, Sutherland GR. Recombinant factor Ⅶ a plus surgery for intracerebral hemorrhage[J]. Can J Neurol Sci, 2008, 35:567-572.
[60] Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A meta-analysis of the efficacy and safety of recombinant activated factor Ⅶ for patients with acute intracerebral hemorrhage without hemophilia[J]. J Clin Neurosci, 2010, 17:685-693.
[61] Dewhirst E. Towards evidence-based emergency medicine:best BETs from the Manchester Royal Infirmary:BET 2:is recombinant factor Ⅶ a beneficial in the management of acute spontaneous intracerebral haemorrhage[J]? Emerg Med J, 2013, 30:340-341.
[62] Gladstone DJ, Aviv RI, Demchuk AM, Hill MD, Thorpe KE, Khoury JC, Sucharew HJ, Al-Ajlan F, Butcher K, Dowlatshahi D, Gubitz G, De Masi S, Hall J, Gregg D, Mamdani M, Shamy M, Swartz RH, Del Campo CM, Cucchiara B, Panagos P, Goldstein JN, Carrozzella J, Jauch EC, Broderick JP, Flaherty ML; SPOTLIGHT and STOP-IT Investigators and Coordinators. Effect of recombinant activated coagulation factor Ⅶ on hemorrhage expansion among patients with spot sign-positive acute intracerebral hemorrhage:the SPOTLIGHT and STOP-IT randomized clinical trials[J]. JAMA Neurol, 2019, 76:1493-1501.
[63] Li Y, Zheng J, Zhou H, Yang X, Li H. Comparison of hemostatic agents in patients with spontaneous intracerebral hemorrhage:a protocol for a network meta-analysis[J]. Medicine (Baltimore) 2020, 99:e22876.

Please choose a citation manager

Content to export